LegitUser
Gluttonmaxxed gypsy from the council estate
- Joined
- Apr 30, 2024
- Posts
- 1,467
- Reputation
- 1,704
What is this and how to use it:
The table has been taken for a review article comparing the treatments available for the skin conditions in the title.
How to use it:
Table 2: New Oral and Topical Treatments
Table 2: New Oral and Topical Treatments
BID: twice daily; FGF: fibroblast growth factor; GSH: glutathione; MASI: Melasma Area Severity Index; MSH: melanocyte-stimulating hormone; SPF: sun protection factor; TSH: thyroid-stimulating hormone; UV: ultraviolet
Table 1: Current established treatments
The table has been taken for a review article comparing the treatments available for the skin conditions in the title.
How to use it:
- Choose the most effective treatments, by looking at the adverse events collumn and seeing what is within your risk tolerance
- Do not choose multiple treatments that work via the same mechanism of action, there is no point
- Cycling tri-luma / TCT / pigmoren and then using treatments from here when you are off TCT cycle will be most effective. TCT = combination of a topical steriod, high strength retinoid, and 4% hydroquinone
Table 2: New Oral and Topical Treatments
Table 2: New Oral and Topical Treatments
Category | Agent | Reference | Mechanism of Action | Dosing | Study Outcomes | Adverse Events |
---|---|---|---|---|---|---|
Photoprotection | Topical Iron Oxide Sunscreens | Boukari et al., 2015; Castanedo-Cazares et al., 2014; Duteil et al., 2017; Lakhdar et al., 2007; Mahmoud et al., 2010; Regazzetti et al., 2018 | Blocks blue visible light | SPF ≥ 50 | UV-visible light regimen had significant improvement | None |
Oral Polypodium leucotomos | Goh et al., 2018; Martin et al., 2013; Nestor et al., 2014; Siscovick et al., 2008 | Promotion of p53 suppressor gene expression; modulation of inflammatory cytokines; ↑ endogenous antioxidant systems; blockade of UV radiation induced cyclooxygenase-2 expression | 240 mg BID | Beneficial effect; Greater reduction in MASI | Mild gastrointestinal upsets | |
Lightening Agents | Oral and Topical Tranexamic Acid | Banihashemi et al., 2015; Del Rosario et al., 2018; Ebrahimi and Naeini, 2014; George, 2016; Kim et al., 2016; Lee et al., 2016; Lee et al., 2017; Na et al., 2013; Perper et al., 2017; Taraz et al., 2017; Wu et al., 2012 | Blocks conversion of plasminogen to plasmin; Blocks binding of plasminogen to keratinocytes; ↓ arachidonic acid release, prostaglandin synthesis, and FGF; ↓ melanin synthesis; ↓ mast cells; ↓ angiogenesis | 2-5% BID (topical); 250 mg BID (oral) | Global studies document significant reduction in MASI score | Oral: mild gastrointestinal discomfort, hypomenorrhea, allergic skin rashes, alopecia, and mild elevations in alanine transaminase; Topical: erythema, scaling, dryness; Propensity to induce thromboembolic phenomena |
Melatonin | Hamadi et al., 2009; Ryoo et al., 2001 | Potent antioxidant/free radical scavenger; ↑ superoxide dismutase, glutathione reductase, glutathione peroxidase; ↓ α-MSH receptors | 5% BID (topical); 3 mg daily (oral) | Decreased MASI; malondialdehyde decreased; GSH levels increased | Not reported | |
GSH | Handog et al., 2016; Sonthalia et al., 2016; Watanabe et al., 2014 | Decreases tyrosinase; skews conversion of eumelanin to pheomelanin | 2% daily (topical); 500 mg daily (oral) | Melanin index significantly reduced | Intravenous: Stevens-Johnson Syndrome, anaphylaxis; Oral and topical: none | |
Topical | Cysteamine | Besouw et al., 2013; Mansouri et al., 2015 | Radioprotector (via direct scavenging effects of hydroxy radicals); Tyrosinase peroxidase inhibition | 5% daily | Reduced MASI compared to placebo | None reported |
Pigment-correcting Serum | Makino et al., 2016 | Melanocyte activation, melanosome development, melanin synthesis, melanosome transfer; keratinocyte differentiation and desquamation | Comparable efficacy to hydroquinone | Mild irritation | ||
Methimazole | Kasraee et al., 2005; Kasraee et al., 2008 | Potent peroxidase inhibitor; blocks melanin synthesis | 5% daily | No significant changes in serum TSH, free thyroxine, free triiodothyronine levels | Minimal cutaneous side effects | |
Flutamide | Adalatkhah et al., 2011 | Blocks action of endogenous/exogenous testosterone by binding to androgen receptor | 1% daily | MASI/colorimetry effects similar to hydroquinone 4%; Patient satisfaction scores significantly high | None |
BID: twice daily; FGF: fibroblast growth factor; GSH: glutathione; MASI: Melasma Area Severity Index; MSH: melanocyte-stimulating hormone; SPF: sun protection factor; TSH: thyroid-stimulating hormone; UV: ultraviolet
Table 1: Current established treatments
Name | Mechanism of action | Side effects | Reference |
---|---|---|---|
Hydroquinone | Tyrosinase inhibition | Erythema, irritation, exogenous ochronosis | De Caprio, 1999, Grimes, 2009, Nordlund et al., 2006, Tse, 2010 |
Azelaic acid | Tyrosinase inhibition | Stinging, burning, itching, dryness | Hashim et al., 2018, Schulte et al., 2015 |
Kojic acid | Tyrosinase inhibition | Irritation, contact dermatitis | Deo et al., 2013, Lajis et al., 2012, Monteiro et al., 2013 |
Ascorbic acid | Inhibition of reactive oxygen species | No significant adverse event | Al-Niaimi and Chiang, 2017, Pires et al., 2018 |
Retinoids | Downregulation of Tyrosinase | Irritant reaction, dryness, hyperpigmentation | Kang, 2005 |
Corticosteroid treatments | Antiinflammatory and nonselective inhibition of melanogenesis | Telangiectasias, epidermal atrophy, steroid-induced acne, striae, hypopigmentation | Menter, 2004 |
Niacinamide | Inhibition of melanasome transfer | Irritation | Bissett, 2002, Navarrete-Solís et al., 2011, Wohlrab and Kreft, 2014 |
Licorice | Melanin dispersion, tyrosinase inhibition | No significant adverse event | Picardo and Carrera, 2007; Videira et al., 2013 |
Undecylenoyl phenylalanine | Antagonist of α-melanocyte-stimulating hormone, β-adrenergic, stem cell receptors | No significant adverse event | Glowka et al., 2018, Olejnik et al., 2018 |
4-N-butylresorcinol | Tyrosinase inhibition, antioxidant, antiinflammatory | Mild erythema and itching | Huh et al., 2010; Wargniez et al., 2017 |
Soybean | Inhibits melanosome transfer to keratinocytes | No significant adverse event | Birk, 1985, Paine et al., 2001 |
Arbutin | Inhibition of tyrosinase | Skin irritation | Sarma et al., 2017 |
Glucosamine | Inhibition of tyrosinase activation | Skin rash | Niwano et al., 2018 |
Mequinol | Inhibition of tyrosinase | Skin irritation, redness, peeling | Keeling et al., 2008 |
Last edited: